Gilead 2Q Revenues: $2.7 billion (+15%) 2Q Earnings: $767.6 million (+9%) YTD Revenues: $5.1 billion (+12%) YTD Earnings: $1.5 billion (+30%) Comments: Antiviral product sales were up 15% to $2.3 billion in the quarter, driven by Viread, up 16% to $250.2 million, and Complera/Eviplera, up 159% to $188.7 million, along with Atripla sales, up 4% to $938.1 million, Truvada sales, up 3% to $807.8 million. Additionally, the company launched Stribild, which generated $99.4 million in sales. Cardi...